5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum.

Let's take a closer look at five of this past week's biggest scorchers.

Company

May 11 Weekly Gain My Watchlist
Arena Pharmaceuticals (Nasdaq: ARNA  ) $6.36 146% Add
Vertex Pharmaceuticals (Nasdaq: VRTX  ) $62.02 66% Add
Rosetta Stone (NYSE: RST  ) $13.64 29% Add
Accretive Health (NYSE: AH  ) $10.86 27% Add
Achillion Pharmaceuticals (Nasdaq: ACHN  ) $7.20 20% Add

Source: Barron's.

Arena Pharmaceuticals was last week's biggest winner, soaring 146% after an advisory committee showed support for its lorcaserin weight-loss treatment. Several obesity drugs are battling it out for regulatory approval, and the stocks themselves will pack on the pounds or shed them as the victors emerge.

The market's second biggest gainer was another biotech. Vertex rose in a sluggish market after releasing promising clinical data for its VX-809 and Kalydeco drugs in the treatment of cystic fibrosis.

Rosetta Stone investors know that applause doesn't need a translation. The language learning program company posted stronger-than-expected quarterly results. Revenue soared above estimates, and Rosetta Stone posted a much smaller deficit than what Wall Street was targeting.

Accretive Health may have slashed its outlook, but analysts preferred to focus on the health care services provider's ability to surpass market expectations in its latest quarter.

Finally we have Achillion moving higher after reporting a narrowing quarterly deficit, offering up encouraging development news, and snagging a UBS analyst upgrade.

More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.

The Motley Fool owns shares of Rosetta Stone. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals and Rosetta Stone. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1886339, ~/Articles/ArticleHandler.aspx, 10/21/2014 5:11:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement